Lilly

Immune Design adds Carlos Paya as CEO

Wednesday, April 27, 2011 01:22 PM

Seattle-based vaccine developer Immune Design’s new CEO is Carlos Paya, the former president of Ireland-based biotech Elan. Paya is replacing Immune Design’s founding CEO, Steve Reed, who will continue to serve on the company’s executive management team and board, according to Xconomy Seattle.

More... »

Eli Lilly 's new anti-psychotic offers no weight gain

Wednesday, April 27, 2011 12:49 PM

The schizophrenia drug Zyprexa was one of Eli Lilly's biggest success stories; however, the company has also paid big settlements regarding claims that it hid data about a burdensome weight-gain side effect. As a result, Lilly has begun late-stage trials for a next-generation schizophrenia drug that offers treatment without weight gain, according to FierceBiotech.

More... »

Lilly and Medtronic to collaborate on Parkinson’s research

Tuesday, April 26, 2011 01:11 PM

Eli Lilly and Medtronic will collaborate to research and develop a new approach to treating Parkinson's disease.  The new approach involves investigating the delivery of a new medicine to the brain using an implantable drug delivery system. The goal is to develop a therapeutic approach to treating Parkinson's disease that combines Lilly's biologic, a modified form of glial cell derived neurotrophic factor (GDNF), with Medtronic's implantable drug infusion system technology.

More... »

Report: Some sponsors more prepared to lead the way in personalized medicine than others

Monday, April 18, 2011 08:05 AM

As the pharmaceutical industry’s investment in personalized medicine leads to development of an increasing number of targeted therapies, particularly for cancer patients, some drug sponsors have shown greater commitment and more structure in their approach than others, according to a new report by consulting firm Diaceutics.

More... »

Eli Lilly CEO says company won’t merge

Tuesday, March 22, 2011 11:25 AM

Eli Lilly, which faces plunging sales due to competition and lapsing patents, will not merge with another company, CEO John Lechleiter said, according to Reuters.

More... »

Pfizer talking with CROs to fill R&D hub

Wednesday, March 16, 2011 12:33 PM

A U.K. task force—assembled to salvage as many R&D jobs at Sandwich as it can before Pfizer completes its planned exit—has confirmed that the pharma giant is in discussions with CROs that may step in to hire some of the 2,400 workers being let go, according to Fierce Biotech.

More... »

Lilly names Plowman VP

Tuesday, March 15, 2011 01:31 PM

Indianapolis-based Eli Lilly has named Dr. Greg Plowman vice president of oncology research and senior vice president of ImClone Systems.

More... »

Diabetes phase II study shows positive results

Monday, March 14, 2011 01:50 PM

Amylin Pharmaceuticals, Eli Lilly and Alkermes announced positive results from a phase II study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type II diabetes.

More... »

Lilly CEO confident in FDA approval

Monday, March 14, 2011 01:31 PM

Eli Lilly CEO John Lechleiter said he's confident of gaining U.S. regulatory approval for a drug to help identify plaque in the brain associated with Alzheimer's disease, according to a Bloomberg News report.

More... »

Report: Big Pharmas embracing technology as they transform to ‘holistic healthcare entities’

Monday, March 14, 2011 07:00 AM

Pharmaceutical companies—having outsourced R&D functions to CROs and collaborated with biotechs, drug companies and academic groups for innovative products and platforms—are now embracing a different type of innovation: technology.

More... »